Ifosfamide

Generic Name: Ifosfamide

Brand Names: Ifex

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 3778-73-2

Unique Ingredient Identifier: UM20QQM95Y

Background: Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent.

Indication: Used as a component of various chemotherapeutic regimens as third-line therapy for recurrent or refractory germ cell testicular cancer. Also used as a component of various chemotherapeutic regimens for the treatment of cervical cancer, as well as in conjunction with surgery and/or radiation therapy in the treatment of various soft tissue sarcomas. Other indi...

Associated Conditions: Bladder Cancer, Cervical Cancer, Ewing's Sarcoma, Head And Neck Cancer, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma (NHL), Osteosarcoma, Ovarian Cancer, Pancreatic Cancer, Small Cell Lung Cancer (SCLC), Soft Tissue Sarcoma, Testicular Germ Cell Cancer, Thymoma

Associated Therapies: -

Clinical Trials

Repeated Bone Marrow Transplantation in Treating Women With Advanced Breast Cancer

Phase 1

Terminated

Conditions: Breast Cancer

First Posted Date: 2004-02-09

Last Posted Date: 2020-07-14

Lead Sponsor: Louisiana State University Health Sciences Center Shreveport

Target Recruit Count: 12

Registration Number: NCT00003086

Locations: 🇺🇸
Louisiana State University School of Medicine, Shreveport, Louisiana, United States

Combination Chemotherapy Plus Dexrazoxane in Treating Patients With Newly Diagnosed Nonmetastatic Osteosarcoma

Phase 3

Completed

Conditions: Cardiac Toxicity
Sarcoma

Interventions: Drug: cisplatin
Drug: dexrazoxane hydrochloride
Drug: doxorubicin hydrochloride
Drug: methotrexate
Drug: ifosfamide
Drug: etoposide
Procedure: conventional surgery

First Posted Date: 2004-02-09

Last Posted Date: 2014-08-05

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 253

Registration Number: NCT00003937

Locations: 🇺🇸
St. Christopher's Hospital for Children, Philadelphia, Pennsylvania, United States
🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States

and more 145 locations

Combination Chemotherapy in Treating Patients With Metastatic Kidney Cancer

Phase 2

Completed

Conditions: Kidney Cancer

First Posted Date: 2004-01-27

Last Posted Date: 2021-02-21

Lead Sponsor: UNICANCER

Target Recruit Count: 40

Registration Number: NCT00003683

Locations: 🇫🇷
Institut Sainte Catherine, Avignon, France
🇫🇷
CRLCC Nantes - Atlantique, Nantes-Saint Herblain, France
🇫🇷
C.H.U. - Hopital Gaston Doumergue, Nimes, France

and more 11 locations

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Germ Cell Tumors

Phase 2

Terminated

Conditions: Childhood Germ Cell Tumor
Testicular Germ Cell Tumor
Extragonadal Germ Cell Tumor
Ovarian Cancer

First Posted Date: 2004-01-27

Last Posted Date: 2016-06-23

Lead Sponsor: UNICANCER

Target Recruit Count: 45

Registration Number: NCT00003852

Locations: 🇫🇷
Centre Jean Perrin, Clermont-Ferrand, France
🇫🇷
Centre de Lute Contre le Cancer,Georges-Francois Leclerc, Dijon, France
🇫🇷
Centre Leon Berard, Lyon, France

and more 15 locations

Combination Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Mantle Cell Lymphoma

Phase 1

Completed

Conditions: Lymphoma

First Posted Date: 2004-01-23

Last Posted Date: 2013-06-24

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 24

Registration Number: NCT00003541

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Combination Chemotherapy With Bone Marrow Transplantation in Treating Men With Germ Cell Tumors

Phase 3

Completed

Conditions: Extragonadal Germ Cell Tumor
Testicular Germ Cell Tumor

First Posted Date: 2004-01-15

Last Posted Date: 2021-02-23

Lead Sponsor: UNICANCER

Target Recruit Count: 280

Registration Number: NCT00002566

Locations: 🇫🇷
Institut Gustave Roussy, Villejuif, France

Surgery and/or Chemotherapy in Treating Children With Infantile, Congenital, or Childhood Fibrosarcoma

Phase 2

Terminated

Conditions: Sarcoma

Interventions: Biological: dactinomycin
Drug: cyclophosphamide
Drug: etoposide
Drug: ifosfamide
Drug: vincristine sulfate
Procedure: Conventional Surgery
Biological: MESNA (mercaptoethane sulfonate)
Biological: Filgrastim

First Posted Date: 2003-11-06

Last Posted Date: 2014-09-30

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 7

Registration Number: NCT00072280

Locations: 🇺🇸
Kosair Children's Hospital, Louisville, Kentucky, United States
🇺🇸
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Spectrum Health Hospital - Butterworth Campus, Grand Rapids, Michigan, United States

and more 71 locations

Cisplatin and Ifosfamide Combined With Either Paclitaxel or Vinblastine in Treating Men With Progressive or Recurrent Metastatic Germ Cell Tumors

Phase 3

Terminated

Conditions: Extragonadal Germ Cell Tumor
Testicular Germ Cell Tumor

Interventions: Drug: cisplatin
Drug: ifosfamide
Drug: paclitaxel
Drug: vinblastine

First Posted Date: 2003-11-06

Last Posted Date: 2016-07-04

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 1

Registration Number: NCT00072215

Locations: 🇺🇸
Broward General Medical Center, Fort Lauderdale, Florida, United States
🇺🇸
Memorial Cancer Institute at Memorial Regional Hospital, Hollywood, Florida, United States
🇺🇸
Palm Beach Cancer Institute - West Palm Beach, West Palm Beach, Florida, United States

and more 76 locations

Chemotherapy, SU5416, Radiation Therapy, and Surgery in Treating Patients With Soft Tissue Sarcoma

Phase 1

Completed

Conditions: Sarcoma

First Posted Date: 2003-10-21

Last Posted Date: 2013-06-24

Lead Sponsor: Radiation Therapy Oncology Group

Registration Number: NCT00023738

Locations: 🇺🇸
USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States
🇺🇸
Harbor Hospital Center, Baltimore, Maryland, United States
🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

and more 223 locations

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Neuroblastoma

Phase 2

Completed

Conditions: Neuroblastoma

Interventions: Biological: filgrastim
Biological: sargramostim
Drug: carboplatin
Drug: cisplatin
Drug: cyclophosphamide
Drug: doxorubicin hydrochloride
Drug: etoposide
Drug: etoposide phosphate
Drug: ifosfamide
Drug: isotretinoin
Drug: melphalan
Drug: thiotepa
Drug: vincristine sulfate
Procedure: conventional surgery
Procedure: peripheral blood stem cell transplantation
Radiation: radiation therapy

First Posted Date: 2003-10-09

Last Posted Date: 2014-02-13

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 42

Registration Number: NCT00017368

Locations: 🇺🇸
CCOP - Columbia River Oncology Program, Portland, Oregon, United States
🇺🇸
Floating Hospital for Children, Boston, Massachusetts, United States
🇺🇸
CCOP - Marshfield Clinic Research Foundation, Marshfield, Wisconsin, United States

and more 6 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy